Transchem Share Price & Earnings Call Analysis
- Market cap
- ₹508 Cr
- P/E
- 75.59
- ROE
- 5.29%
- PEG
- 1.31
- Debt to equity
- 0.00
- 52W high / low
- ₹419 / ₹64.8
- Net profit margin
- 198.86%
- Promoter holding
- 56.45%
Transchem Ltd has transitioned from mushroom manufacturing and exports to financial services. After selling its non-operational Pune mushroom undertaking in 2020, it primarily earned through inter-corporate deposits and treasury investments.[1][2]
Potential multibaggers · Q2 FY27
Potential multibaggers in Pharmaceuticals & Biotechnology
on management's own guidance
- Strong growth2
- Strong growth1
- Strong growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Peers
Pharmaceuticals & Biotechnology companies ranked on guidance
| # | Company | Revenue guided | Margin guided | Market cap | P/E |
|---|---|---|---|---|---|
| 1 | 40%+ | Up 2%+ | ₹480 Cr | 19.1 | |
| 2 | 40%+ | Up 0–2% | ₹212 Cr | 16.1 | |
| 3 | 40%+ | Flat | ₹17,925 Cr | — | |
| 4 | 40%+ | Flat | ₹5,223 Cr | 39.1 | |
| 5 | 40%+ | Flat | ₹4,268 Cr | — | |
| 6 | 40%+ | Flat | ₹40 Cr | — |
Sign up free to see every company in the sector ranking and track Transchem.
Pro shows every company guiding 40%+ revenue growth →Full Pharmaceuticals & Biotechnology rankingFinancials of Transchem
Quarterly Results, Profit & Loss, Balance Sheet, Cash Flows, and Ratios are shown below as separate sections.
Financials of Transchem
Quarterly Results
Quarter-by-quarter operating performance
| Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales + | 0.00 | 0.00 | 0.00 | 0.00 | 0.41 | 0.00 | 0.00 | 0.21 | 2.42 | 0.00 | 0.00 | 0.00 | 0.00 |
| Expenses + | 0.48 | 0.40 | 0.39 | 0.50 | 0.86 | 0.27 | 0.37 | 0.54 | 2.90 | 0.29 | 0.75 | 1.31 | 1.31 |
| Operating Profit | -0.48 | -0.40 | -0.39 | -0.50 | -0.45 | -0.27 | -0.37 | -0.33 | -0.48 | -0.29 | -0.75 | -1.31 | -1.31 |
| OPM % | -109.76% | -157.14% | -19.83% | ||||||||||
| Other Income + | 1.03 | 1.53 | 1.69 | 2.02 | 2.16 | 2.47 | 2.31 | 2.19 | 1.56 | 1.64 | 1.68 | 2.25 | 3.70 |
| Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Profit before tax | 0.55 | 1.13 | 1.30 | 1.52 | 1.71 | 2.20 | 1.94 | 1.86 | 1.08 | 1.35 | 0.93 | 0.94 | 2.39 |
| Tax % | 25.45% | 24.78% | 25.38% | 25.66% | 26.90% | 24.09% | 25.26% | 25.27% | 32.41% | 26.67% | 27.96% | 43.62% | 12.55% |
| Net Profit + | 0.41 | 0.85 | 0.97 | 1.14 | 1.25 | 1.66 | 1.44 | 1.39 | 0.73 | 0.99 | 0.68 | 0.53 | 2.09 |
| EPS in Rs | 0.33 | 0.69 | 0.79 | 0.93 | 1.02 | 1.36 | 1.18 | 1.14 | 0.60 | 0.81 | 0.56 | 0.43 | 1.71 |
Financials of Transchem
Profit & Loss
Annual income statement trend
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales + | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -0.05 | -0.20 | 0.00 | 0.34 | 2.57 | 0.00 |
| Expenses + | 0.78 | 0.93 | 0.98 | 1.69 | 1.18 | 1.39 | 1.88 | 2.54 | 1.73 | 2.08 | 4.03 | 3.64 |
| Operating Profit | -0.78 | -0.93 | -0.98 | -1.69 | -1.18 | -1.39 | -1.93 | -2.74 | -1.73 | -1.74 | -1.46 | -3.64 |
| OPM % | -511.76% | -56.81% | ||||||||||
| Other Income + | 2.09 | 1.97 | 1.78 | 2.11 | 2.75 | 2.76 | 26.82 | 6.66 | 4.24 | 7.40 | 8.53 | 9.26 |
| Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation | 1.07 | 1.02 | 1.02 | 0.97 | 0.80 | 0.57 | 0.12 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 |
| Profit before tax | 0.24 | 0.02 | -0.22 | -0.55 | 0.77 | 0.80 | 24.77 | 3.91 | 2.50 | 5.65 | 7.06 | 5.61 |
| Tax % | 45.83% | -150.00% | 0.00% | 116.36% | 61.04% | 47.50% | 2.50% | 26.60% | 50.80% | 25.66% | 26.06% | 23.53% |
| Net Profit + | 0.12 | 0.05 | -0.22 | -1.19 | 0.31 | 0.41 | 24.15 | 2.87 | 1.24 | 4.20 | 5.23 | 4.30 |
| EPS in Rs | 0.10 | 0.04 | -0.18 | -0.97 | 0.25 | 0.33 | 19.73 | 2.34 | 1.01 | 3.43 | 4.27 | 3.51 |
| Dividend Payout % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Financials of Transchem
Balance Sheet
Capital structure and asset base
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 12.24 | 12.24 | 12.24 | 12.24 | 12.24 | 12.24 | 12.24 | 12.24 | 12.24 | 12.24 | 12.24 | 12.24 |
| Reserves | 26.11 | 26.15 | 25.75 | 24.57 | 25.74 | 24.53 | 50.70 | 54.06 | 53.60 | 63.41 | 67.08 | 71.34 |
| Borrowings + | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Liabilities + | 0.22 | 0.23 | 0.17 | 0.17 | 0.39 | 0.30 | 0.48 | 0.51 | 0.39 | 0.66 | 0.40 | 4.15 |
| Total Liabilities | 38.57 | 38.62 | 38.16 | 36.98 | 38.37 | 37.07 | 63.42 | 66.81 | 66.23 | 76.31 | 79.72 | 87.73 |
| Fixed Assets + | 8.40 | 7.42 | 6.40 | 5.43 | 4.27 | 3.70 | 0.11 | 0.10 | 0.09 | 0.09 | 0.05 | 0.02 |
| CWIP | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Investments | 27.50 | 28.01 | 29.79 | 10.21 | 5.93 | 3.69 | 8.69 | 8.82 | 8.23 | 8.91 | 2.04 | 1.97 |
| Other Assets + | 2.67 | 3.19 | 1.97 | 21.34 | 28.17 | 29.68 | 54.62 | 57.89 | 57.91 | 67.31 | 77.63 | 85.74 |
| Total Assets | 38.57 | 38.62 | 38.16 | 36.98 | 38.37 | 37.07 | 63.42 | 66.81 | 66.23 | 76.31 | 79.72 | 87.73 |
Financials of Transchem
Cash Flows
Operating, investing and financing cash movement
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash from Operating Activity + | 0.94 | 1.08 | 0.55 | -19.79 | 10.34 | -0.63 | -27.72 | 21.91 | 1.22 | -39.31 | 36.00 | -1.57 |
| Cash from Investing Activity + | -1.21 | -0.26 | -1.51 | 19.78 | 5.73 | 0.67 | 23.06 | 0.60 | -0.94 | 5.12 | 6.02 | 1.65 |
| Cash from Financing Activity + | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Cash Flow | -0.27 | 0.83 | -0.95 | -0.01 | 16.07 | 0.04 | -4.66 | 22.51 | 0.28 | -34.18 | 42.02 | 0.09 |
| Free Cash Flow | 0.94 | 1.04 | 0.55 | -19.79 | 10.53 | -0.63 | -1.79 | 21.91 | 1.22 | -39.31 | 36.53 | 0.01 |
| CFO/OP | -121% | -116% | -56% | 1,165% | -897% | 0% | 1,401% | -853% | -132% | 2,182% | -2,618% | 10% |
Financials of Transchem
Ratios
Working capital efficiency and return ratios
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 0.00 | 0.00 | 440.15 | 384.88 | ||||||||
| Inventory Days | 35,770.00 | 32,485.00 | -511.00 | -273.75 | 0.00 | 0.00 | ||||||
| Days Payable | 0.00 | 0.00 | ||||||||||
| Cash Conversion Cycle | -511.00 | -273.75 | 440.15 | 384.88 | ||||||||
| Working Capital Days | 311,418.00 | 42,705.00 | 71,421.91 | 4,970.82 | ||||||||
| ROCE % | 0.63% | 0.05% | -0.58% | -1.47% | 1.63% | 2.03% | 4.61% | 4.22% | 3.50% | 7.99% | 9.11% | 6.89% |
Momentum score · price trend
98 out of 100 — Strengthening
Over the past year its share price has done better than most of the stocks we track.
| Period | Share price change | Better than … of 1,910 stocks |
|---|---|---|
| Last 12 months | +515.1% | 100% |
| Last 6 months | +146.8% | 99% |
| Last 3 months | +36.9% | 95% |
How we calculate it
“Better than 30%” means that over that period the share price did better than 30 out of every 100 stocks we track (1,910 Indian companies worth ₹500 Cr or more, with at least a year of prices).
The score weighs the longer periods more: 40% × 12-month + 40% × 6-month + 20% × 3-month. For Transchem: 0.4 × 100 + 0.4 × 99 + 0.2 × 95 = 98.
Strengthening is 70 and above, Steady 40 to 70, Cooling below 40. Scores are recalculated every night after the market closes.
Full methodology →This describes only how the share price has moved up to 2 Nov 2026, compared with other stocks. It says nothing about the business, and it is not a prediction, a price target or a recommendation to buy or sell.
Continue your research
Others in Pharmaceuticals & Biotechnology this season
- Anthem Bioscienc (Q2 FY27)
Q2FY27 Consolidated Revenue from Operations: ₹5,940 Mn, up 7.9% YoY from ₹5,505 Mn in Q2FY26 (Page 4). Key investor presentation takeaways from Anthem Bioscienc
- Neuland Laboratories (Q2 FY27)
Q2FY27 Total Income (revenue) was ₹457.2 crore, down 11.4% year-on-year (YoY) from Q2FY26. Key investor presentation takeaways from Neuland Laboratories Ltd's Q
- Hikal (Q2 FY27)
Consolidated Revenue Q2FY27:** ₹434 crores, up 36% YoY from ₹319 crores in Q2FY26 (Page 9) . Key investor presentation takeaways from Hikal Ltd's Q2 FY27 invest
- Kopran (Q2 FY27)
9,335 lakhs (~79% increase) . Key investor presentation takeaways from Kopran Ltd's Q2 FY27 investor presentation — and how it ranks against sector peers.